180 related articles for article (PubMed ID: 35237856)
1. Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
Fischer C; Deutsch TM; Feisst M; Rippinger N; Riedel F; Hartkopf AD; Brucker SY; Domschke C; Fremd C; Michel L; Burwinkel B; Schneeweiss A; Turchinovich A; Wallwiener M
Arch Gynecol Obstet; 2022 Sep; 306(3):875-885. PubMed ID: 35237856
[TBL] [Abstract][Full Text] [Related]
2. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
Fischer C; Turchinovich A; Feisst M; Riedel F; Haßdenteufel K; Scharli P; Hartkopf AD; Brucker SY; Michel L; Burwinkel B; Schneeweiss A; Wallwiener M; Deutsch TM
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076930
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
Papadaki C; Stratigos M; Markakis G; Spiliotaki M; Mastrostamatis G; Nikolaou C; Mavroudis D; Agelaki S
Breast Cancer Res; 2018 Jul; 20(1):72. PubMed ID: 29996899
[TBL] [Abstract][Full Text] [Related]
4. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
5. Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia.
Zhou JD; Zhang LC; Zhang TJ; Gu Y; Wu DH; Zhang W; Ma JC; Wen XM; Guo H; Lin J; Qian J
J Transl Med; 2018 May; 16(1):135. PubMed ID: 29784043
[TBL] [Abstract][Full Text] [Related]
6. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis.
Madhavan D; Peng C; Wallwiener M; Zucknick M; Nees J; Schott S; Rudolph A; Riethdorf S; Trumpp A; Pantel K; Sohn C; Chang-Claude J; Schneeweiss A; Burwinkel B
Carcinogenesis; 2016 May; 37(5):461-70. PubMed ID: 26785733
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
Cao Q; Lu K; Dai S; Hu Y; Fan W
Int J Clin Exp Pathol; 2014; 7(5):2392-401. PubMed ID: 24966949
[TBL] [Abstract][Full Text] [Related]
8. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
9. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.
Papadaki C; Stoupis G; Tsalikis L; Monastirioti A; Papadaki M; Maliotis N; Stratigos M; Mastrostamatis G; Mavroudis D; Agelaki S
Oncotarget; 2019 Jan; 10(9):966-981. PubMed ID: 30847025
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of miR-200 family in breast cancer: A meta-analysis and systematic review.
Thi Chung Duong T; Nguyen THN; Thi Ngoc Nguyen T; Huynh LH; Ngo HP; Thi Nguyen H
Cancer Epidemiol; 2022 Apr; 77():102097. PubMed ID: 35030348
[TBL] [Abstract][Full Text] [Related]
11. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
[TBL] [Abstract][Full Text] [Related]
12. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: A consideration on heterogeneity.
Yuan L; Bing Z; Yan P; Li R; Wang C; Sun X; Yang J; Shi X; Zhang Y; Yang K
Gene; 2019 Oct; 716():144025. PubMed ID: 31394177
[TBL] [Abstract][Full Text] [Related]
13. The miR-200 family as prognostic markers in clear cell renal cell carcinoma.
Saleeb R; Kim SS; Ding Q; Scorilas A; Lin S; Khella HW; Boulos C; Ibrahim G; Yousef GM
Urol Oncol; 2019 Dec; 37(12):955-963. PubMed ID: 31635993
[TBL] [Abstract][Full Text] [Related]
14. Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
Masuda T; Shinden Y; Noda M; Ueo H; Hu Q; Yoshikawa Y; Tsuruda Y; Kuroda Y; Ito S; Eguchi H; Ohno S; Mimori K
Anticancer Res; 2018 Aug; 38(8):4515-4523. PubMed ID: 30061217
[TBL] [Abstract][Full Text] [Related]
15. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
16. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
19. A microRNA signature associated with early recurrence in breast cancer.
Pérez-Rivas LG; Jerez JM; Carmona R; de Luque V; Vicioso L; Claros MG; Viguera E; Pajares B; Sánchez A; Ribelles N; Alba E; Lozano J
PLoS One; 2014; 9(3):e91884. PubMed ID: 24632820
[TBL] [Abstract][Full Text] [Related]
20. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
